| BCG vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
|---|---|
| brucella strain 19 vaccine | A live bacterial vaccine prepared from an attenuated variant strain of Brucella abortus (strain 19); used for vaccinating cattle against brucellosis. (05 Mar 2000) |
| brucella vaccine | A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats. (12 Dec 1998) |
| Calmette-Guerin vaccine | <drug> Live attenuated vaccine for tuberculosis. For groups and health care workers in high endemic areas. Not to be given to individuals with HIV infection. (15 Nov 1997) |
| rabies vaccine | An inactivated virus vaccine, used for preexposure immunization to persons at high risk of exposure, e.g., veterinarians, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. The official preparation is human diploid cell vaccine produced from rabies virus grown in cultures of human diploid embryo lung cells and inactivated with propriolactone. It has a much lower incidence of adverse reactions than the previously used duck embryo vaccine. (12 Dec 1998) |
| vaccine | <pharmacology> A suspension of attenuated or killed microorganisms (bacteria, viruses or rickettsiae), administered for the prevention, amelioration or treatment of infectious diseases. Origin: L. Vaccinus (18 Nov 1997) |
| vaccine bodies | Old term pertaining to intracellular body's that were erroneously thought to be forms in the life cycle of a protozoan organism, Cytorrhyctes vaccinae, postulated to be the causal agent of vaccinia. (05 Mar 2000) |
| vaccine, flu | The flu (influenza) vaccine is recommended for persons at high risk for serious complications from influenza infection, including everyone 65 or over; people with chronic diseases of the heart, lung or kidneys, diabetes, immunosuppression, or severe forms of anaemia; residents of nursing homes and other chronic-care facilities, children and teenagers taking aspirin therapy (and who may therefore be at risk for developing reye syndrome after an influenza infection), and those in close or frequent contact with anyone at high risk. Persons with an allergy to eggs should not receive influenza vaccine. (12 Dec 1998) |
| vaccine lymph | Vaccinia lymph, that collected from the vesicles of vaccinia infection, and used for active immunization against smallpox. (05 Mar 2000) |
| variola vaccine | <dermatology> The cutaneous and sometimes systemic reactions associated with vaccination with smallpox vaccine. (18 Nov 1997) |
| measles, mumps and rubella vaccine | A combination of live attenuated measles, mumps, and rubella viruses in an aqueous suspension; used for immunization against the respective diseases. (05 Mar 2000) |
| measles vaccine | A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunised with live measles vaccine and have no serum antibodies against measles. Children are usually immunised with measles-mumps-rubella combination vaccine. (12 Dec 1998) |
| measles virus vaccine | Vaccine containing live, attenuated strains of measles virus prepared in chick embryo cell culture. See: measles, mumps, and rubella vaccine. (05 Mar 2000) |
| Pasteur vaccine | An inactivated virus vaccine, used for preexposure immunization to persons at high risk of exposure, e.g., veterinarians, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis. The official preparation is human diploid cell vaccine produced from rabies virus grown in cultures of human diploid embryo lung cells and inactivated with propriolactone. It has a much lower incidence of adverse reactions than the previously used duck embryo vaccine. (12 Dec 1998) |
| chickenpox vaccine | <pharmacology, virology> A live-varicella virus vaccine. Limited clinical trials suggest the immunity lasts for at least six years. The only significant adverse reaction detected in clinical studies was pain and redness at the injection site. Children (or adults) with a history for an anaphylactoid reaction to neomycin or gelatin or the presence of any febrile illness, should not be given the vaccine. Pregnant women and those who are immunocompromised should also not receive the vaccine. It is furthermore recommended that pregnancy be avoided for 3 months following vaccination. In trials involving 9,000 children, 80% were protected and 20% reported mild cases. It is recommended for children between the ages of 12 months and 13 years. (12 Dec 1998) |